This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2009 Jun;15(5):414-6.

doi: 10.18553/jmcp.2009.15.5.414.

Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel

Frederic R Curtiss, Kathleen A Fairman

PMID: 19496638
PMCID: PMC10437957
DOI: 10.18553/jmcp.2009.15.5.414

Comparative Study

Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel

Frederic R Curtiss et al. J Manag Care Pharm. 2009 Jun.

. 2009 Jun;15(5):414-6.

doi: 10.18553/jmcp.2009.15.5.414.

Authors

Frederic R Curtiss, Kathleen A Fairman

PMID: 19496638
PMCID: PMC10437957
DOI: 10.18553/jmcp.2009.15.5.414

No abstract available

PubMed Disclaimer

Comment on

Critical review of prasugrel for formulary decision makers.
Schafer JA, Kjesbo NK, Gleason PP. Schafer JA, et al. J Manag Care Pharm. 2009 May;15(4):335-43. doi: 10.18553/jmcp.2009.15.4.335. J Manag Care Pharm. 2009. PMID: 19422273 Free PMC article. Review.
Review of prasugrel for the secondary prevention of atherothrombosis.
Spinler SA, Rees C. Spinler SA, et al. J Manag Care Pharm. 2009 Jun;15(5):383-95. doi: 10.18553/jmcp.2009.15.5.383. J Manag Care Pharm. 2009. PMID: 19496635 Free PMC article. Review.

Similar articles

Cost is not a barrier to implementing clopidogrel pharmacogenetics.
Cavallari LH, Schumock GT. Cavallari LH, et al. Pharmacotherapy. 2012 Apr;32(4):299-303. doi: 10.1002/j.1875-9114.2012.01107.x. Pharmacotherapy. 2012. PMID: 22461119 No abstract available.
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Reese ES, et al. Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048. Pharmacotherapy. 2012. PMID: 22461122 Free PMC article.
Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
Davies A, Sculpher M, Barrett A, Huete T, Sacristán JA, Dilla T. Davies A, et al. Farm Hosp. 2013 Jul-Aug;37(4):307-16. doi: 10.7399/FH.2013.37.4.687. Farm Hosp. 2013. PMID: 24010692
Prasugrel (Effient) vs. clopidogrel (Plavix).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70. Med Lett Drugs Ther. 2009. PMID: 19738549 Review.
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M. Greenhalgh J, et al. Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Health Technol Assess. 2010. PMID: 20507801 Review.

See all similar articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information